SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
644Telegraph Hill Partners Acquires Instrumentation Assets of Aurora Instruments LLnigel bates-12/4/2003
643* Phase I programs ** ** VX-563 - Not planning to continue ** Based on pharmacomopgcw-11/12/2003
642b**s*** small message limit on SI now?? pipeline part 2: ** Lexiva approved andmopgcw-11/12/2003
641Chuckle. let alone the mgmt cash-in at the same time. here is the GS summary omopgcw-11/12/2003
640<i>Vertex is uniquely positioned as a leader in chemistry and the developmHarold Engstrom-11/12/2003
639GS Snip: Vertex announced with partner Aventis, plans to discontinue Phase IIbmopgcw-11/11/2003
638Vertex has recently completed clinical studies with two additional compounds, anrkrw-11/11/2003
637Pipeline update tucked in after the merimepodib news... HCV protease into phaserkrw-11/11/2003
636Very, very desperate times! But, management knows how to crews SH. For this theMiljenko Zuanic-11/10/2003
635Part II: Non-clinical Toxicology Results The purpose of toxicology studies is Miljenko Zuanic-11/10/2003
634Od ZUDIJE ZUDIJA, and so on... <<The discontinued phase IIb studies were Miljenko Zuanic-11/10/2003
633>>Bioorg Med Chem Lett. 2003 Nov 17;13(22):4059-63. Inhibitors of hepattuck-11/5/2003
632WSJ: The FDA's Approval of Drugs Doesn't Ensure Biotech Riches It may tom pope-10/30/2003
631GS Note: Vertex Pharmaceuticals, Inc. EPS (FY Dec) 2003E ($2.05), 2004E ($2.11)mopgcw-10/21/2003
630Tuck, I think that you are too little cautious. As Jim noted, VX-497 should beMiljenko Zuanic-10/19/2003
629Tuck, you're not being overly cautious. The study proved nothing. It reads mrkrw-10/18/2003
628Not much meat in the recent release about the interim results for VX-497 (see prtuck-10/18/2003
627>>CAMBRIDGE, Mass., Oct. 17 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticatuck-10/17/2003
626Goldman Sachs: Vertex Pharmaceuticals, Inc. EPS (FY Dec) 2003E ($2.05), 2004E (mopgcw-10/6/2003
625So, why did they discontinue RA indication? Press Release Source: Pharmacopeia,Miljenko Zuanic-8/12/2003
624>>NEW YORK, July 24 (Reuters) - Vertex Pharmaceuticals Inc. (NasdaqNM:VRTXtuck-7/24/2003
623Press Release Source: Vertex Pharmaceuticals Incorporated Aventis and Vertex PMiljenko Zuanic-7/10/2003
622Vertex lays off 111 in Cambridge, Calif. By Naomi Aoki and Christopher Rowland,sim1-6/11/2003
621>>CAMBRIDGE, Mass., May 21 /PRNewswire-FirstCall/-- Vertex Pharmaceuticalstuck-5/21/2003
62009:36 ET VRTX Vertex Pharm initiated with Underperform at Morgan Stanley (10.Doc Bones-4/15/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News